Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor
cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib
mesylate works as first-line therapy in treating patients with locally advanced or metastatic
pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey